[1] Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153: 420–429.
[2] Peterson WL. Helicobacter pylori and Peptic Ulcer Disease. New England Journal of Medicine 1991; 324: 1043–1048.
[3] Caselli M, Alvisi V. Helicobacter pylori and peptic-ulcer disease. The Lancet 2002; 359: 1943–1944.
[4] Henriksson AE, Edman AC, Held M, et al. Helicobacter pylori and acute bleeding peptic ulcer. Eur J Gastroenterol Hepatol 1995; 7: 769–771.
[5] Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: a state of the art review. Gastroenterol Hepatol Bed Bench 2015; 8: S6–S14.
[6] Wotherspoon AC. Gastric MALT lymphoma and Helicobacter pylori. Yale J Biol Med 1996; 69: 61–68.
[7] Kim BJ, Kim HS, Jang HJ, et al. Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials. Gastroenterol Res Pract; 2018. Epub ahead of print 9 October 2018. DOI: 10.1155/2018/6090878.
[8] Monzón H, Forné M, Esteve M, et al. Helicobacter pylori infection as a cause of iron deficiency anaemia of unknown origin. World J Gastroenterol 2013; 19: 4166–4171.
[9] Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1–241.
[10] Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China: A Randomized Controlled Trial | Gastroenterology | JAMA | JAMA Network, https://jamanetwork.com/journals/jama/fullarticle/197985 (accessed 4 July 2020).
[11] Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J Methodol 2015; 5: 164–174.
[12] Savoldi A, Carrara E, Graham DY, et al. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155: 1372-1382.e17.
[13] Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6–30.
[14] Cheha KM, Dib SOA, Alhalabi MM. Pilot study: Comparing efficacy of 14-day triple therapy Clarithromycin versus levofloxacin on eradication of Helicobacter pylori infection in Syrian population single-center experience. Avicenna J Med 2018; 8: 14–17.
[15] Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology; 112, https://journals.lww.com/ajg/Fulltext/2017/02000/ACG_Clinical_Guideline__Treatment_of_Helicobacter.12.aspx (2017).
[16] Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. Digestion 2016; 93: 167–173.
[17] Moshkowitz M, Konikoff FM, Peled Y, et al. One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. Alimentary Pharmacology & Therapeutics 1996; 10: 1015–1019.
[18] Satoh K, Kimura K, Taniguchi Y, et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol 1998; 93: 569–573.
[19] Lee JY, Kim N. Diagnosis of Helicobacter pylori by invasive test: histology. Ann Transl Med; 3. Epub ahead of print January 2015. DOI: 10.3978/j.issn.2305-5839.2014.11.03.
[20] Veijola L, Myllyluoma E, Korpela R, et al. Stool antigen tests in the diagnosis of Helicobacter pylori infection before and after eradication therapy. World J Gastroenterol 2005; 11: 7340–7344.
[21] Federico A, Nardone G, Gravina AG, et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012; 143: 55-61.e1; quize e13-14.
[22] Martínez-Mesa J, González-Chica DA, Bastos JL, et al. Sample size: how many participants do I need in my research? Anais Brasileiros de Dermatologia 2014; 89: 609–615.
[23] Omair A. Sample size estimation and sampling techniques for selecting a representative sample. Journal of Health Specialties 2014; 2: 142–147.
[24] Sakpal TV. Sample Size Estimation in Clinical Trial. Perspect Clin Res 2010; 1: 67–69.
[25] Graham DY, Lu H, Yamaoka Y. A Report Card to Grade Helicobacter pylori Therapy. Helicobacter 2007; 12: 275–278.
[26] Essa AS, Kramer JR, Graham DY, et al. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing ‘concomitant therapy’ versus triple therapy for Helicobacter pylori eradication. Centre for Reviews and Dissemination (UK), https://www.ncbi.nlm.nih.gov/books/NBK77292/ (2009, accessed 4 September 2020).
[27] Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; CD008337.
[28] Haddadi M-H, Negahdari B, Asadolahi R, et al. Helicobacter pylori antibiotic resistance and correlation with cagA motifs and homB gene. Postgrad Med 2020; 1–9.
[29] Levy SB, Star L, Kupferberg ED. The misuse of antibiotics. Medical ethics (Burlington, Mass) 2004; 11: 5–8.
[30] Schroeck JL, Ruh CA, Sellick JA, et al. Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. Antimicrobial agents and chemotherapy 2015; 59: 3848–3852.
[31] Grob PR. Antibiotic prescribing practices and patient compliance in the community. Scand J Infect Dis Suppl 1992; 83: 7–14.
[32] Eells SJ, Nguyen M, Jung J, et al. Relationship between Adherence to Oral Antibiotics and Postdischarge Clinical Outcomes among Patients Hospitalized with Staphylococcus aureus Skin Infections. Antimicrobial Agents and Chemotherapy 2016; 60: 2941–2948.
[33] Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 2002; 49: 897–903.
[34] Nsimba SED. Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy. East Afr J Public Health 2008; 5: 205–210.
[35] Caudron J-M, Ford N, Henkens M, et al. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 2008; 13: 1062–1072.